Patients with peripheral artery disease undergoing percutaneous peripheral interventions are at increased risk for complications without adequate anticoagulation

Journal of Invasive Cardiology

Volumn 16, Issue 12 SUPPL. G, 2004, Pages 18-20

  Allie, David E ^a  

^a Cardiovascular Institute of the South   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; ARTERY DISEASE; BLEEDING; BLOOD CLOTTING TIME; BOLUS INJECTION; CLINICAL TRIAL; CONFERENCE PAPER; FEMORAL ARTERY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; ILIAC ARTERY; PERCUTANEOUS CORONARY INTERVENTION; RENAL ARTERY; THROMBOCYTOPENIA; THROMBOSIS; VASCULAR ACCESS;

ANTICOAGULANTS; CONSTRICTION, PATHOLOGIC; ENDOVASCULAR PROCEDURES; HEPARIN; HIRUDINS; HUMANS; ILIAC ARTERY; PEPTIDE FRAGMENTS; PERIPHERAL ARTERIAL DISEASE; RECOMBINANT PROTEINS; RENAL ARTERY OBSTRUCTION;

EID: 13144262854     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Cimminello C. PAD - Epidemiology and pathophysiology. Thrombosis Research 2002;106:V295-V301.
2. Shammas NW, Lemke JH, Dippel EJ, et al. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invas Cardiol 2003;15:242-246.
3. Allie DE, Lirtzman MD, Wyatt CH, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: A safe and feasible alternative for renal and iliac interventions. J Invas Cardiol 2003;15:334-342.
4. Lacoste L, Lan JYT, Hung J, et al. Hyperlipidemia and coronary disease. Circulation 1995;92:3172-3177.
5. Tsang J, Sheppard R, Mak KH, et al. Six-month outcomes of percutaneous transluminal coronary angioplasty in hypertensive patients: Results for the ROSETTA registry. Am Heart J 2002 Jan;143(1):124-129.
6. Sica D. The implications of renal impairment among patients undergoing percutaneous coronary intervention. J Invas Cardiol 2002;14:30B-37B.
7. Henry TD. Overcoming heparin limitations in high-risk PCI: The alternative strategy - replacing heparin with bivalirudin. J Invas Cardiol 2002;14:19B-29B.
8. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invas Cardiol 2000;12:27F-32F.
9. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995;74:1-6.
10. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue-factor induced blood coagulation. Blood 2002;100(1):148-152.
11. White CJ, Ramee SR. Coronary angioscopy. In: Topol E (ed). ed. textbook of Interventional Cardiology. Philadelphia, PA: Saunders Company; 1999:783-800.
12. White CJ, Ramee SR, Collins T, et al. Coronary thrombi increase PTCA risk: Angioscopy as a clinical tool. Circulation 1994;93:253-258.
13. Bhatt DL. Heparin in peripheral vascular intervention - Time for a change? J Invas Cardiol 2003;15(5):249-250.
14. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
15. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
16. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-961.
17. Blankenship JC, Hellkamp AS, Aguirre FV, et al. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Trial. Am J Cardiol 1998;81:36-40.
18. Messina LM, Brothers TE, Wakefield TW, et al. Clinical characteristics and surgical management of vascular complications in patients undergoing cardiac catheterization: Interventional versus diagnostic procedures. J Vasc Surg 1991 May;13(5):593-600.
19. Kuchulakanti PK, Sailer LF, Suddath WO, et al. Vascular complications following coronary intervention correlate with long-term cardiac events. Catheter Cardiovasc Interv 2004;62:181-185.
20. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and heparin. Am J Cardiol 1998;82:12P-18P.
21. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993;69(2):157-163.
22. Shammas NW, Lemke JH, Dippel EJ, et al. Bivalirudin in peripheral vascular interventions: A single center experience. J Invas Cardiol 2003;15:401-404.
23. Grubbs G. Single center experience with bivalirudin anticoagulation in peripheral vascular interventions: Possible benefits over unfractionated heparin. Poster presented at: Cardiovascular Revascularization Therapy conference; January 26-29, 2003; Washington, DC.
24. Knopf W. St. Joseph's Hospital experience; Direct thrombin inhibitors in ACS and PCI: The case for bivalirudin replacing unfractionated heparin in PCl. Paper presented at: Transcatheter Cardiovascular Therapeutics 14th Annual Scientific Symposium; September 24-28, 2003; Washington, DC.
25. Allie DE, Hall P, Shammas NW, et al. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): In-hospital and 30-day results. J Invas Cardiol 2004;16(11):651-656.